Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 101

1.

The formation of estrogen-like tamoxifen metabolites and their influence on enzyme activity and gene expression of ADME genes.

Johänning J, Kröner P, Thomas M, Zanger UM, Nörenberg A, Eichelbaum M, Schwab M, Brauch H, Schroth W, Mürdter TE.

Arch Toxicol. 2018 Mar;92(3):1099-1112. doi: 10.1007/s00204-017-2147-y. Epub 2017 Dec 28.

2.

Activity levels of tamoxifen metabolites at the estrogen receptor and the impact of genetic polymorphisms of phase I and II enzymes on their concentration levels in plasma.

Mürdter TE, Schroth W, Bacchus-Gerybadze L, Winter S, Heinkele G, Simon W, Fasching PA, Fehm T; German Tamoxifen and AI Clinicians Group, Eichelbaum M, Schwab M, Brauch H.

Clin Pharmacol Ther. 2011 May;89(5):708-17. doi: 10.1038/clpt.2011.27. Epub 2011 Mar 30. Erratum in: Clin Pharmacol Ther. 2012 Jun;91(6):1087.

PMID:
21451508
3.

The Cytochrome P450 Enzyme Responsible for the Production of (Z)-Norendoxifen in vitro.

Ma J, Chu Z, Lu JBL, Liu J, Zhang Q, Liu Z, Tang D.

Chem Biodivers. 2018 Jan;15(1). doi: 10.1002/cbdv.201700287. Epub 2017 Dec 28.

PMID:
28834279
4.

Multigene and Drug Interaction Approach for Tamoxifen Metabolite Patterns Reveals Possible Involvement of CYP2C9, CYP2C19, and ABCB1.

Powers JL, Buys SS, Fletcher D, Melis R, Johnson-Davis KL, Lyon E, Malmberg EM, McMillin GA.

J Clin Pharmacol. 2016 Dec;56(12):1570-1581. doi: 10.1002/jcph.771. Epub 2016 Jun 21.

PMID:
27198207
5.

The influence of CYP2B6, CYP2C9 and CYP2D6 genotypes on the formation of the potent antioestrogen Z-4-hydroxy-tamoxifen in human liver.

Coller JK, Krebsfaenger N, Klein K, Endrizzi K, Wolbold R, Lang T, Nüssler A, Neuhaus P, Zanger UM, Eichelbaum M, Mürdter TE.

Br J Clin Pharmacol. 2002 Aug;54(2):157-67.

6.

Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine.

Stearns V, Johnson MD, Rae JM, Morocho A, Novielli A, Bhargava P, Hayes DF, Desta Z, Flockhart DA.

J Natl Cancer Inst. 2003 Dec 3;95(23):1758-64.

PMID:
14652237
7.

Highly sensitive simultaneous quantification of estrogenic tamoxifen metabolites and steroid hormones by LC-MS/MS.

Johänning J, Heinkele G, Precht JC, Brauch H, Eichelbaum M, Schwab M, Schroth W, Mürdter TE.

Anal Bioanal Chem. 2015 Sep;407(24):7497-502. doi: 10.1007/s00216-015-8907-8. Epub 2015 Jul 25.

PMID:
26206706
8.

Endoxifen (4-hydroxy-N-desmethyl-tamoxifen) has anti-estrogenic effects in breast cancer cells with potency similar to 4-hydroxy-tamoxifen.

Lim YC, Desta Z, Flockhart DA, Skaar TC.

Cancer Chemother Pharmacol. 2005 May;55(5):471-8. Epub 2005 Feb 1.

PMID:
15685451
9.

Biotransformation of tamoxifen in a human endometrial explant culture model.

Sharma M, Shubert DE, Sharma M, Lewis J, McGarrigle BP, Bofinger DP, Olson JR.

Chem Biol Interact. 2003 Dec 15;146(3):237-49.

PMID:
14642736
10.

Reversible and irreversible inhibition of CYP3A enzymes by tamoxifen and metabolites.

Zhao XJ, Jones DR, Wang YH, Grimm SW, Hall SD.

Xenobiotica. 2002 Oct;32(10):863-78.

PMID:
12419016
11.

Comparative metabolic study between two selective estrogen receptor modulators, toremifene and tamoxifen, in human liver microsomes.

Watanabe M, Watanabe N, Maruyama S, Kawashiro T.

Drug Metab Pharmacokinet. 2015 Oct;30(5):325-33. doi: 10.1016/j.dmpk.2015.05.004. Epub 2015 May 29.

PMID:
26423799
12.

Limited predictive value of achieving beneficial plasma (Z)-endoxifen threshold level by CYP2D6 genotyping in tamoxifen-treated Polish women with breast cancer.

Hennig EE, Piatkowska M, Karczmarski J, Goryca K, Brewczynska E, Jazwiec R, Kluska A, Omiotek R, Paziewska A, Dadlez M, Ostrowski J.

BMC Cancer. 2015 Aug 1;15:570. doi: 10.1186/s12885-015-1575-4.

13.
14.

Elimination of antiestrogenic effects of active tamoxifen metabolites by glucuronidation.

Zheng Y, Sun D, Sharma AK, Chen G, Amin S, Lazarus P.

Drug Metab Dispos. 2007 Oct;35(10):1942-8. Epub 2007 Jul 9.

PMID:
17620345
15.

Contribution of human cytochrome p-450 isoforms to the metabolism of the simplest phenothiazine neuroleptic promazine.

Wójcikowski J, Pichard-Garcia L, Maurel P, Daniel WA.

Br J Pharmacol. 2003 Apr;138(8):1465-74.

16.

The tamoxifen metabolite norendoxifen is a potent and selective inhibitor of aromatase (CYP19) and a potential lead compound for novel therapeutic agents.

Lu WJ, Xu C, Pei Z, Mayhoub AS, Cushman M, Flockhart DA.

Breast Cancer Res Treat. 2012 May;133(1):99-109. doi: 10.1007/s10549-011-1699-4. Epub 2011 Aug 4.

PMID:
21814747
17.

Reductive amination-assisted quantitation of tamoxifen and its metabolites by liquid phase chromatography tandem mass spectrometry.

Liang SS, Wang TN, Chiu CC, Kuo PL, Huang MF, Liu MC, Tsai EM.

J Chromatogr A. 2016 Feb 19;1434:64-9. doi: 10.1016/j.chroma.2016.01.015. Epub 2016 Jan 11.

PMID:
26814364
18.

Inhibition of cytochrome p450 enzymes by the e- and z-isomers of norendoxifen.

Liu J, Flockhart PJ, Lu D, Lv W, Lu WJ, Han X, Cushman M, Flockhart DA.

Drug Metab Dispos. 2013 Sep;41(9):1715-20. doi: 10.1124/dmd.113.052506. Epub 2013 Jul 3.

19.

Estrogen receptor-beta sensitizes breast cancer cells to the anti-estrogenic actions of endoxifen.

Wu X, Subramaniam M, Grygo SB, Sun Z, Negron V, Lingle WL, Goetz MP, Ingle JN, Spelsberg TC, Hawse JR.

Breast Cancer Res. 2011 Mar 10;13(2):R27. doi: 10.1186/bcr2844.

20.

Effects of Pharmacogenetics on the Pharmacokinetics and Pharmacodynamics of Tamoxifen.

de Vries Schultink AH, Zwart W, Linn SC, Beijnen JH, Huitema AD.

Clin Pharmacokinet. 2015 Aug;54(8):797-810. doi: 10.1007/s40262-015-0273-3. Review.

Supplemental Content

Support Center